Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Co-amoxiclav is a combination antibiotic containing amoxicillin, a broad-spectrum penicillin-type beta-lactam antibiotic, and clavulanic acid, a beta-lactamase inhibitor. The addition of clavulanic acid extends the spectrum of amoxicillin to include bacteria that produce beta-lactamase enzymes, making it effective against many resistant strains. It is used for various infections including respiratory tract infections, urinary tract infections, skin and soft tissue infections, sinusitis, otitis media, and dental infections[3][5]. Dicloxacillin is a narrow-spectrum penicillin-class antibiotic designed to resist degradation by beta-lactamases produced by certain Gram-positive bacteria such as Staphylococcus aureus. It is primarily used for mild-to-moderate staphylococcal skin and soft tissue infections (including impetigo), osteomyelitis, septic arthritis, pneumonia (as adjunct), throat infections caused by susceptible organisms, endocarditis prophylaxis in some cases, and surgical prophylaxis[6]. Both drugs act by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on co-amoxiclav or dicloxacillin.